Health biotechnology in China--reawakening of a giant.
作者信息
Zhenzhen Li, Jiuchun Zhang, Ke Wen, Thorsteinsdóttir Halla, Quach Uyen, Singer Peter A, Daar Abdallah S
机构信息
Sociology for Science and Policy of S&T, Institute of Policy and Management, Chinese Academy of Sciences, Zhong guan-cun East Road No. 55, P.O. Box 8712, Beijing 100080, China.
出版信息
Nat Biotechnol. 2004 Dec;22 Suppl(Suppl 12):DC13-8. doi: 10.1038/nbt1204supp-DC13.
Abstract
摘要
相似文献
1
Health biotechnology in China--reawakening of a giant.
Nat Biotechnol. 2004 Dec;22 Suppl(Suppl 12):DC13-8. doi: 10.1038/nbt1204supp-DC13.
2
Conclusions: promoting biotechnology innovation in developing countries.
Nat Biotechnol. 2004 Dec;22 Suppl(Suppl 12):DC48-52. doi: 10.1038/nbt1204supp-DC48.
3
South Africa--blazing a trail for African biotechnology.
Nat Biotechnol. 2004 Dec;22 Suppl:DC37-41. doi: 10.1038/nbt1204supp-DC37.
4
Cuba--innovation through synergy.
Nat Biotechnol. 2004 Dec;22 Suppl:DC19-24. doi: 10.1038/nbt1204supp-DC19.
5
Indian biotechnology--rapidly evolving and industry led.
Nat Biotechnol. 2004 Dec;22 Suppl:DC31-6. doi: 10.1038/nbt1204supp-DC31.
6
South Korean biotechnology--a rising industrial and scientific powerhouse.
Nat Biotechnol. 2004 Dec;22 Suppl:DC42-7. doi: 10.1038/nbt1204supp-DC42.
7
The emergence of Egyptian biotechnology from generics.
Nat Biotechnol. 2004 Dec;22 Suppl:DC25-30. doi: 10.1038/nbt1204supp-DC25.
8
The scientific muscle of Brazil's health biotechnology.
Nat Biotechnol. 2004 Dec;22 Suppl:DC8-12. doi: 10.1038/nbt1204supp-DC8.
9
Introduction: promoting global health through biotechnology.
Nat Biotechnol. 2004 Dec;22 Suppl:DC3-7. doi: 10.1038/nbt1204supp-DC3.
10
The development of China's medical biotech industry needs to be driven by innovation.
Biotechnol J. 2006 Nov;1(11):1253-7. doi: 10.1002/biot.200600086.
引用本文的文献
1
Determinants of biopharmaceutical R&D expenditures in China: the impact of spatiotemporal context.
Scientometrics. 2021;126(8):6659-6680. doi: 10.1007/s11192-021-04058-y. Epub 2021 Jun 23.
2
Bioinformatics and the Politics of Innovation in the Life Sciences: Science and the State in the United Kingdom, China, and India.
Sci Technol Human Values. 2016 Sep;41(5):793-826. doi: 10.1177/0162243916631022. Epub 2016 Feb 24.
3
The case for conducting first-in-human (phase 0 and phase 1) clinical trials in low and middle income countries.
BMC Public Health. 2011 Oct 18;11:811. doi: 10.1186/1471-2458-11-811.
4
Health biotechnology innovation on a global stage.
Nat Rev Microbiol. 2011 Feb;9(2):137-43. doi: 10.1038/nrmicro2492.
5
Globetrotting firms: Canada's health biotechnology collaborations with developing countries.
Nat Biotechnol. 2009 Sep;27(9):806-14. doi: 10.1038/nbt0909-806.
本文引用的文献
1
IP litigation in China could drive innovation.
Nat Biotechnol. 2004 Apr;22(4):368. doi: 10.1038/nbt0404-368.
2
An embryonic nation.
Nature. 2004 Mar 11;428(6979):210-2. doi: 10.1038/428210a.
3
The new Silk Road.
Nature. 2004 Mar 11;428(6979):208-9. doi: 10.1038/428208a.
4
Making an impact.
Nature. 2004 Mar 11;428(6979):206-7. doi: 10.1038/428206a.
5
Cultural reflections.
Nature. 2004 Mar 11;428(6979):204-5. doi: 10.1038/428204a.
6
Embryonic stem cells generated by nuclear transfer of human somatic nuclei into rabbit oocytes.
Cell Res. 2003 Aug;13(4):251-63. doi: 10.1038/sj.cr.7290170.
7
SARS in China. China's missed chance.
Science. 2003 Jul 18;301(5631):294-6. doi: 10.1126/science.301.5631.294.
8
A draft sequence of the rice genome (Oryza sativa L. ssp. indica).
Science. 2002 Apr 5;296(5565):79-92. doi: 10.1126/science.1068037.
9
The rice genome. Beijing Genomics Institute: from standing start to sequencing superpower.
Science. 2002 Apr 5;296(5565):36-9. doi: 10.1126/science.296.5565.36.
Zotero 插件